

**4<sup>th</sup> Think Tank**  
on Advancing  
Gastroesophageal  
Cancer Research  
November 12, 2020

# MEETING PROGRAM

---

PRESENTED BY  
Adam Bass, MD & TargetCancer Foundation



TargetCancer  
Foundation



**4<sup>th</sup> Think Tank**  
on Advancing  
Gastroesophageal  
Cancer Research  
November 12, 2020

---

Thank you for joining the 2020 Think Tank on Advancing Gastroesophageal Cancer Research. We are sorry that we can't meet in person, but we are excited to present the Think Tank virtually and welcome a large international community this year. While we can not replicate the in-person conversations and networking that make the Think Tank so valuable, we hope that the presentations today will still lead to new collaborations, define research priorities for the field, and ultimately accelerate the identification of new treatments.

Our sincere thanks to our partners who worked with us to plan this meeting and its conversion to a virtual format over the past year: Drs. Julian Abrams, Jim Goldenring, Sam Klempner, Monika Laszkowska, and Matthew Stachler.

We hope that you enjoy today's program, and look forward to gathering again in person soon.

Jim Palma  
TargetCancer Foundation

Adam Bass, MD  
Dana-Farber Cancer Institute



# AGENDA

THURSDAY, NOVEMBER 12, 2020

---

**8:45-8:55a WELCOME & INTRODUCTIONS**

**9:00-10:25a MAIN SESSION**

**Clonal transitions and phenotypic evolution in Barrett's Esophagus**

Stuart McDonald, PhD, *Barts Cancer Institute*

**Multimodal tethered capsule endomicroscopy for improved diagnosis of Barrett's Esophagus**

Andreas Wartak, PhD, *Massachusetts General Hospital and Harvard Medical School*

**Modeling Esophageal Adenocarcinoma in the mouse model**

Michael Quante, MD, *University of Freiburg*

**10:25-10:35a STRETCH & BYO COFFEE**

**10:35-11:20a RAPID-FIRE ABSTRACT PRESENTATIONS**

**Pre-existing tumor-infiltrating T cells influence response to neoadjuvant chemotherapy in Esophageal Adenocarcinoma**

Ruben Goedegebuure, MD, *Amsterdam UMC*

**Proanthocyanidins enhance chemotherapy induced Esophageal Adenocarcinoma cell death**

Laura Kresty, MS, PhD, *University of Michigan*

**Increased HNF4A dosage regulates CDX2 expression in intestinal metaplasia via binding a novel unguarded enhancer**

Harshabad Singh, MBBS, *Dana-Farber Cancer Institute*

**11:25-12:15p MAIN SESSION CONTINUED**

**Oral health and risk of upper gastrointestinal cancers in a large prospective study from a high-risk region: Golestan Cohort Study**

Yukiko Yano, PhD, *National Cancer Institute*

**Chronic inflammation and cancer**

Thea Tlsty, PhD, *University of California, San Francisco*

**12:20-12:30p CLOSING REMARKS**

# SPEAKERS

---



**STUART MCDONALD, MD**  
BARTS CANCER INSTITUTE

Twitter: [@mcdona02](#)

<https://www.bartscancer.london/staff/dr-stuart-mcdonald/>



**MICHAEL QUANTE, PhD**  
UNIVERSITY OF FREIBURG

Twitter: [@QuanteMichael](#)

<https://www.quantelab.org/people.html>



**THEA TLSTY, PhD**  
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

[http://cancer.ucsf.edu/people/profiles/tlsty\\_thea.3688](http://cancer.ucsf.edu/people/profiles/tlsty_thea.3688)



## TOP-TIER ABSTRACTS

---

**Andreas Wartak, PhD**

Massachusetts General Hospital, Harvard Medical School

*Multimodal tethered capsule endomicroscopy for improved diagnosis of Barrett's Esophagus*

**Yukiko Yano, PhD**

National Cancer Institute

*Oral health and risk of upper gastrointestinal cancers in a large prospective study from a high-risk region: Golestan Cohort Study*

## RAPID-FIRE ABSTRACTS

---

**Laura Kresty, MS, PhD**

Univeristy of Michigan

*Proanthocyanidins enhance chemotherapy induced Esophageal Adenocarcinoma cell death*

**Ruben Goedegebuure, MD**

Amsterdam UMC

*Pre-existing tumor-infiltrating T cells influence response to neoadjuvant chemotherapy in esophageal adenocarcinoma*

**Harshabad Singh, MBBS**

Dana-Farber Cancer Institute

*Increased HNF4A dosage regulates CDX2 expression in intestinal metaplasia via binding a novel un-guarded enhancer*

# TRACK

TARGET → RARE → CANCER → KNOWLEDGE

## Driving precision medicine in rare cancers.

**TCF-001 TRACK is a prospective clinical study (NCT04504604) seeking to enroll 400 patients with rare cancers or cancer of unknown primary.**

TRACK was developed by TargetCancer Foundation in collaboration with academic investigators and in partnership with Foundation Medicine.

### **TCF-001 TRACK Goals and Objectives:**

- Perform comprehensive genomic profiling of tissue and blood (FoundationOne CDx & FoundationOne Liquid CDx) at no cost to patients.
- Convene an expert Virtual Molecular Tumor Board (VMTB) to provide recommendations for on-label, off-label, or clinical trial treatments.
- Utilize remote consenting to allow patients to enroll from their homes, eliminating travel requirements and expanding study geographic reach.
- Track patient outcomes for a minimum of one year, repeating FoundationOne Liquid CDx 2-3 times and providing additional VMTB recommendations based on discovery of new actionable alterations.
- Characterize the genomic landscape of rare cancers.

**To learn more about TCF-001 TRACK, contact Jim Palma at [jim@targetcancerfoundation.org](mailto:jim@targetcancerfoundation.org), or visit [targetcancerfoundation.org/track](https://targetcancerfoundation.org/track).**




TargetCancer  
Foundation

## Through multiple efforts, TargetCancer Foundation is driving the gastroesophageal cancer research field forward:

- A seven-year commitment to funding innovative and impactful esophageal cancer research at the Bass Lab at the Dana-Farber Cancer Institute, focusing on genomic studies and the role of immunotherapy.
- Support for studies around a key immunotherapy clinical trial, which has led to an improved treatment opportunity for esophageal cancer patients.
- Hosting the annual Think Tank on Advancing Gastroesophageal Cancer Research, a unique scientific meeting that fosters collaboration and idea generation among leading clinicians, researchers, advocates and patients.
- Partnering with Count Me In at the Broad Institute of MIT and Harvard on the development of the **Esophageal and Stomach Cancer Project**, an initiative that partners with patients to generate critical research data. Learn more at: [www.escproject.org](http://www.escproject.org).

## TargetCancer Foundation also drives other rare cancer programs:

- Developing innovative rare cancer studies, such as TCF-001 TRACK, which impact patients directly while simultaneously generating critical research data.
- Providing over ten years of funding for innovative, high-impact cholangiocarcinoma research focusing on the development of cell lines, mouse models, and genomic studies.
- Lowering barriers to clinical trials through direct patient guidance and comprehensive genomic profiling awareness and access programs.
- Serving as a public voice to raise awareness of the challenges faced by the rare cancer patient and research community, and leading a nationwide coalition of advocacy foundations devoted to rare cancers.



**TargetCancer Foundation** promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer Foundation directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.



# TargetCancer Foundation

For more information, visit  
[www.targetcancerfoundation.org](http://www.targetcancerfoundation.org)

One Broadway, 14th Floor  
Cambridge, MA 02142  
[info@targetcancerfoundation.org](mailto:info@targetcancerfoundation.org)  
617-765-4881

